Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $139.19 USD
Change Today +0.56 / 0.40%
Volume 88.4K
BIO On Other Exchanges
New York
New York
As of 8:04 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

bio-rad laboratories-a (BIO) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/15/15 - $152.38
52 Week Low
11/5/14 - $102.71
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIO-RAD LABORATORIES-A (BIO)

Related News

No related news articles were found.

bio-rad laboratories-a (BIO) Related Businessweek News

View More BusinessWeek News

bio-rad laboratories-a (BIO) Details

Bio-Rad Laboratories, Inc. manufactures and supplies products and systems used to separate complex chemical and biological materials, as well as to identify, analyze, and purify their components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls that serve clinical laboratories in the diagnostics market. Its products include reagents, instruments, and software, which address specific niches within the in vitro diagnostics (IVD) test market. This segment sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians’ office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force and a service network. It has operations in Europe, Pacific Rim, the United States, and internationally. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

7,600 Employees
Last Reported Date: 03/2/15
Founded in 1952

bio-rad laboratories-a (BIO) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $843.1K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $423.3K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $609.0K
Executive Vice President and President of Cli...
Total Annual Compensation: $432.6K
Chief Strategy Officer and Executive Vice Pre...
Total Annual Compensation: $425.7K
Compensation as of Fiscal Year 2014.

bio-rad laboratories-a (BIO) Key Developments

Bio-Rad Laboratories Launches New Blood Typing and Screening System

Bio-Rad Laboratories, Inc. has launched the IH-500, a fully automated random access system for blood typing and screening. IH-500 provides small and medium-size transfusion medicine laboratories fast and reliable results in a 24/7 environment. The IH-500 system is available in Europe, Asia, Africa, Australia, and Latin America. The IH-500 system can handle the entire range of Bio-Rad ID gel cards for ABO blood grouping, reverse testing, phenotype, Rh-subgroups, antibody screening, antibody identification, single antigen testing, direct AHG testing (DAT), and crossmatch. The system incorporates a 6-axis robot transport arm offering a high level of automation and minimizing user operations. The IH-500 system also offers enhanced safety checks, extended reagent storage, and dynamic sample work flow management that provides additional efficiencies. The seamless integration of IH-500 with IH-Com (software for data management and results interpretation) and IH-Web (software for remote result management) significantly improves the workflow from small labs to large lab networks.

Bio-Rad Laboratories, Inc. Announces Earnings Results for the Second Quarter and First Half Ended June 30, 2015; Provides Earnings Guidance for the Full Year of 2015

Bio-Rad Laboratories, Inc. announced earnings results for the second quarter and first half ended June 30, 2015. For the quarter, the company reported revenues of $506.1 million, down 5.7% compared to $536.8 million reported for the second quarter of 2014. On a currency-neutral basis, quarterly revenues increased 4.2% compared to the same period last year. Second-quarter gross margin was 55.2% compared to 55.4% reported during the same quarter in 2014. Net income for the second quarter of 2015 was $28.4 million, or $0.97 per share on a fully diluted basis, compared to $31.6 million, or $1.09 per share, respectively, during the same period last year. The year-over-year decrease of net income for the second quarter of 2015 was primarily due to the impact of currency as well as several discrete items including an increase of $2.6 million of bad debt expense, a one-time distributor termination expense of $1.9 million, and a change of $1.7 million of expense reflecting the revaluation of contingent consideration for certain acquisitions. Effective income tax rate for the second quarter of 2015 was 28% compared to the tax rate for the second quarter of 2014 of 35%. The lower tax rate in 2015 was due to a decrease in tax reserves as a result of the expiration of statutes of limitation. Net capital expenditures for the quarter were $32.2 million, which is a slight increase both sequentially and year-over-year. For the first half, revenues were down 6.4% to $978.9 million compared to $1.05 billion for the same period in 2014. On a currency-neutral basis, revenues grew 2.9%. Net income was $46.2 million, or $1.58 per share on a fully diluted basis, compared to $38.3 million, or $1.32 per share, respectively, during the same period in 2014. Net capital expenditures was $60 million. For the full year of 2015, the company expects CapEx has been in the $130 million to $140 million range. The company expects depreciation to increase, reflecting the successful implementation of second deployment of SAP. The decrease in total depreciation and amortization when compared to the year-ago period is largely related to currency.

Bio-Rad Laboratories, Inc. to Report Q2, 2015 Results on Aug 06, 2015

Bio-Rad Laboratories, Inc. announced that they will report Q2, 2015 results After-Market on Aug 06, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIO:US $139.19 USD +0.56

BIO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $47.03 USD -0.26
Bio-Techne Corp $94.42 USD +0.73
BioMerieux €93.80 EUR -0.63
Cepheid $43.60 USD -0.33
PerkinElmer Inc $48.19 USD +0.31
View Industry Companies

Industry Analysis


Industry Average

Valuation BIO Industry Range
Price/Earnings 41.9x
Price/Sales 1.9x
Price/Book 1.7x
Price/Cash Flow 34.4x
TEV/Sales 1.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIO-RAD LABORATORIES-A, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at